| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 47.6% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 08/22/2023 | 84.5% | Cantor Fitzgerald | → $20 | Reiterates | Overweight → Overweight |
| 07/10/2023 | 47.6% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 04/21/2023 | 102.95% | Needham | → $22 | Reiterates | → Buy |
| 03/10/2023 | 204.43% | Cantor Fitzgerald | $49 → $33 | Maintains | Overweight |
| 03/10/2023 | 47.6% | HC Wainwright & Co. | → $16 | Reiterates | → Buy |
| 03/09/2023 | 102.95% | Needham | $24 → $22 | Reiterates | → Buy |
| 02/03/2023 | 84.5% | SVB Leerink | $30 → $20 | Maintains | Outperform |
| 10/06/2022 | 47.6% | HC Wainwright & Co. | $48 → $16 | Maintains | Buy |
| 10/05/2022 | 176.75% | SVB Leerink | $45 → $30 | Maintains | Outperform |
| 10/04/2022 | 121.4% | Needham | $38 → $24 | Maintains | Buy |
| 07/08/2022 | 315.13% | SVB Leerink | $51 → $45 | Maintains | Outperform |
| 07/08/2022 | 250.55% | Needham | $42 → $38 | Maintains | Buy |
| 06/08/2022 | 195.2% | Stifel | $54 → $32 | Maintains | Buy |
| 03/11/2022 | 287.45% | Needham | $48 → $42 | Maintains | Buy |
| 12/10/2021 | 342.8% | Needham | $50 → $48 | Maintains | Buy |
| 02/18/2021 | 407.38% | Roth Capital | $30 → $55 | Maintains | Buy |
| 02/10/2021 | 370.48% | SVB Leerink | $39 → $51 | Maintains | Outperform |
| 02/10/2021 | 342.8% | HC Wainwright & Co. | $30 → $48 | Maintains | Buy |
| 01/26/2021 | 195.2% | Needham | $25 → $32 | Maintains | Buy |
| 11/17/2020 | 259.78% | SVB Leerink | $28 → $39 | Maintains | Outperform |
| 06/15/2020 | 176.75% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Buy |
| 12/10/2019 | 158.3% | Needham | $35 → $28 | Maintains | Buy |
| 07/29/2019 | 185.98% | SVB Leerink | → $31 | Initiates Coverage On | → Outperform |
| 03/20/2019 | 222.88% | Needham | → $35 | Initiates Coverage On | → Buy |
| 10/30/2018 | 176.75% | Jefferies | → $30 | Initiates Coverage On | → Buy |
| 09/21/2018 | 195.2% | Cantor Fitzgerald | → $32 | Initiates Coverage On | → Overweight |
What is the target price for KalVista Pharma (KALV)?
The latest price target for KalVista Pharma (NASDAQ: KALV) was reported by HC Wainwright & Co. on September 8, 2023. The analyst firm set a price target for $16.00 expecting KALV to rise to within 12 months (a possible 47.60% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for KalVista Pharma (KALV)?
The latest analyst rating for KalVista Pharma (NASDAQ: KALV) was provided by HC Wainwright & Co., and KalVista Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for KalVista Pharma (KALV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KalVista Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KalVista Pharma was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
Is the Analyst Rating KalVista Pharma (KALV) correct?
While ratings are subjective and will change, the latest KalVista Pharma (KALV) rating was a reiterated with a price target of $0.00 to $16.00. The current price KalVista Pharma (KALV) is trading at is $10.84, which is within the analyst's predicted range.